PE20090164A1 - Benzotiofenos y benzofuranos sustituidos con 2-heteroarilo - Google Patents

Benzotiofenos y benzofuranos sustituidos con 2-heteroarilo

Info

Publication number
PE20090164A1
PE20090164A1 PE2008000429A PE2008000429A PE20090164A1 PE 20090164 A1 PE20090164 A1 PE 20090164A1 PE 2008000429 A PE2008000429 A PE 2008000429A PE 2008000429 A PE2008000429 A PE 2008000429A PE 20090164 A1 PE20090164 A1 PE 20090164A1
Authority
PE
Peru
Prior art keywords
benzofuran
methyl
benzophurans
benzothiophenes
heteroaryl
Prior art date
Application number
PE2008000429A
Other languages
English (en)
Spanish (es)
Inventor
Erwan Arzel
Britt-Marie Swahn
David Wensbo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090164A1 publication Critical patent/PE20090164A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
PE2008000429A 2007-03-06 2008-03-05 Benzotiofenos y benzofuranos sustituidos con 2-heteroarilo PE20090164A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
PE20090164A1 true PE20090164A1 (es) 2009-05-03

Family

ID=39738510

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000429A PE20090164A1 (es) 2007-03-06 2008-03-05 Benzotiofenos y benzofuranos sustituidos con 2-heteroarilo

Country Status (23)

Country Link
US (1) US7772256B2 (cg-RX-API-DMAC7.html)
EP (1) EP2132201B1 (cg-RX-API-DMAC7.html)
JP (1) JP5631009B2 (cg-RX-API-DMAC7.html)
KR (1) KR101530392B1 (cg-RX-API-DMAC7.html)
CN (2) CN101675042B (cg-RX-API-DMAC7.html)
AR (1) AR065599A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008221668B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808503B8 (cg-RX-API-DMAC7.html)
CA (1) CA2680157C (cg-RX-API-DMAC7.html)
CL (1) CL2008000645A1 (cg-RX-API-DMAC7.html)
CO (1) CO6220965A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP099641A (cg-RX-API-DMAC7.html)
ES (1) ES2615381T3 (cg-RX-API-DMAC7.html)
IL (1) IL200524A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009009469A (cg-RX-API-DMAC7.html)
MY (1) MY147347A (cg-RX-API-DMAC7.html)
NZ (1) NZ579157A (cg-RX-API-DMAC7.html)
PE (1) PE20090164A1 (cg-RX-API-DMAC7.html)
SA (1) SA08290097B1 (cg-RX-API-DMAC7.html)
TW (1) TW200901998A (cg-RX-API-DMAC7.html)
UA (1) UA98481C2 (cg-RX-API-DMAC7.html)
UY (1) UY30951A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008108730A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
ES2554772T3 (es) 2008-05-30 2015-12-23 Merck Sharp & Dohme Corp. Azabenzoxazoles sustituidos novedosos
WO2010016490A1 (ja) 2008-08-05 2010-02-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
WO2012017891A1 (ja) * 2010-08-06 2012-02-09 国立大学法人京都大学 ピリジルベンゾフラン誘導体
EP3749305A1 (en) * 2018-02-05 2020-12-16 Université de Strasbourg Compounds and compositions for the treatment of pain
AU2020324546A1 (en) * 2019-08-06 2022-03-10 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
EP1334091B1 (en) 2000-08-24 2012-09-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
EP1351936A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
KR20040058111A (ko) 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑/びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20060276433A1 (en) 2003-03-31 2006-12-07 Keiichi Kawagoe Hydrazone derivative
CN100372844C (zh) 2003-05-13 2008-03-05 弗·哈夫曼-拉罗切有限公司 作为腺苷受体配体的2-咪唑-苯并噻唑
EP1644365A2 (en) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2609980C (en) 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
EP2233470B1 (en) * 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
WO2007035405A2 (en) 2005-09-16 2007-03-29 University Of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
EP1945622B1 (en) 2005-10-11 2011-12-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Isotopically-labeled benzofuran compounds as imagingagents for amyloidogenic proteins
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
WO2008118122A2 (en) 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
BRPI0806621A2 (pt) 2007-01-22 2011-09-13 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e, método in vivo para medir depósitos amilóides em um indivìduo
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Also Published As

Publication number Publication date
CN101675042B (zh) 2012-06-13
CA2680157A1 (en) 2008-09-12
WO2008108730A1 (en) 2008-09-12
UA98481C2 (en) 2012-05-25
CL2008000645A1 (es) 2008-10-24
CN102617556A (zh) 2012-08-01
UY30951A1 (es) 2008-10-31
US7772256B2 (en) 2010-08-10
JP2010520276A (ja) 2010-06-10
RU2009133257A (ru) 2011-04-20
AU2008221668A1 (en) 2008-09-12
TW200901998A (en) 2009-01-16
CN101675042A (zh) 2010-03-17
IL200524A0 (en) 2010-04-29
JP5631009B2 (ja) 2014-11-26
CO6220965A2 (es) 2010-11-19
MY147347A (en) 2012-11-30
EP2132201A4 (en) 2011-05-25
CA2680157C (en) 2016-04-12
BRPI0808503B1 (pt) 2020-09-29
AR065599A1 (es) 2009-06-17
EP2132201B1 (en) 2016-11-16
ECSP099641A (es) 2009-10-30
EP2132201A1 (en) 2009-12-16
NZ579157A (en) 2012-04-27
SA08290097B1 (ar) 2011-10-29
BRPI0808503A2 (pt) 2014-08-19
KR101530392B1 (ko) 2015-06-22
ES2615381T3 (es) 2017-06-06
BRPI0808503B8 (pt) 2021-05-25
MX2009009469A (es) 2009-09-15
AU2008221668B2 (en) 2011-03-31
US20080221149A1 (en) 2008-09-11
KR20090117892A (ko) 2009-11-13

Similar Documents

Publication Publication Date Title
PE20090164A1 (es) Benzotiofenos y benzofuranos sustituidos con 2-heteroarilo
PE20081532A1 (es) Compuestos novedosos
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
AR045173A1 (es) Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20060241A1 (es) 2-quinolil-oxazoles sustituidos como inhibidores de pde4
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
DE602004024017D1 (de) Knieprothese mit abnehmbarem Sperrstift zum Begrenzen der Vorwärtsbewegung des Lagers.
PE20081467A1 (es) Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk)
PE20140109A1 (es) Inhibidores del virus de la hepatitis c
ATE440091T1 (de) Antidiabetische bicyclische verbindungen
PE20090641A1 (es) Amidas heterociclicas
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
AR061515A1 (es) Benzoxazoles sustituidos con heteroarilo. composiciones farmaceuticas.
PE20081505A1 (es) Inhibidores de serina palmitoiltransferasa
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
EP2365974A4 (en) FLUORATED BENZOTHIAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND IMAGE-DISPLAYING AGENT FOR THE DIAGNOSIS OF ALZHEIMER DISEASE, WHICH USES THEREOF
PE20110299A1 (es) Nuevos derivados de acilaminobenzamida
PE20091080A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20100734A1 (es) Compuestos de anillo fusionado como activadores de glucoquinasa
NO20061872L (no) Disulfid, sulfid, sulfoksid, og sulfoderivater av sykliske sukkere og anvendelse derav
AR054551A1 (es) Metodos para la neuroproteccion

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed